Atomo wins Best In Show at MDEA

Atomo Diagnostics’ AtomoRapid HIV blood test has been awarded Best In Show and winner in the In Vitro Diagnostics Category of the 17th Medical Design Excellence Awards.

The company’s AtomoRapid platform allows for fast and home-use blood testing for conditions and diseases including HIV, malaria, coeliac disease and allergy.

The AtomoRapid HIV test is on sale in several African countries, and the company also aims to launch the product in the US and Europe.

Atomo CEO John Kelly said the company has the potential to improve the uptake and reliability of HIV testing in the community.

“Clinical performance of standard test kits is proven in the lab, but serious concerns have been raised about in-field performance. This is down to their complex nature, requiring multiple components for the procedure offering resulting in errors, which in turn creates false diagnosis,” he said.

George L Walls, ZOLL director of product and market development, who was one of the 12 judges for the awards program, said Atomo’s test is an example of a real problem creatively and disruptively addressed.

“[The test is] fast, low-cost, accurate and fundamentally changing the use and business model in this important space,” he said. It’s EPT for HIV.”

Atomo is gearing up to launch its second blood test product, AtomoRapid Malaria, in the third quarter.